期刊文献+

分化型甲状腺癌患者^(131)I治疗中核医学医护人员照射剂量的估算 被引量:5

原文传递
导出
摘要 目的估算131I治疗分化型甲状腺癌(DTC)患者住院期间对核医学医护人员的照射剂量(RD)。方法随机选取47例行131I清除DTC术后残留甲状腺的DTC患者,其中男7例,女40例,年龄23~56(41±13)岁。在患者口服131I后1、12、24、48及72h,利用辐射监测剂量仪测量患者1.0m处的照射剂量率(DR),利用指数函数拟合DR-时间曲线。假定核医学医护人员在患者服131I的5d内,每天短暂接触患者1次,接触距离为1.0m,每次接触时间为10min,计算医护人员的RD。结果 DTC患者服131I后1h的DR为15.81~46.48μSv/(h·GBq-1),平均为(27.88±5.72)μSv/(h·GBq-1)。核医学医护人员每接触一位DTC清甲患者,RD为4.02~28.35μSv。结论 DTC患者接受131I治疗期间,核医学医护人员短期接触DTC患者时的照射剂量较低。
出处 《四川大学学报(医学版)》 CAS CSCD 北大核心 2015年第6期937-939,共3页 Journal of Sichuan University(Medical Sciences)
基金 国家自然科学基金(No.81401445 No.81471693)资助
  • 相关文献

参考文献2

二级参考文献16

  • 1Benua RS,Cicale NR,Sonenberg M,et al.The relation of radioiodine desimetry to results and complications in treatment of metastatic thyroid cancer.Am J Roentgenol,1962,87:171-182.
  • 2Stabin MG,Brill AB.State of the art in nuclear medicine dose assessment.Semin Nucl Med,2008,38:308-320.
  • 3Lassmann M,Hanscheid H,Chiesa C,et al.EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I:blood and bone marrow dosimetry in differentiated thyroid cancer therapy.Eur J Nucl Med Mol Imaging,2008,35:1405-1412.
  • 4Akabani G,Poston JW.Absorbed dose calculations to blood and blood vessels for internally deposited radionuelides.J Nucl Med,1991,32:830-834.
  • 5Thomas SR,Samaratunga RC,Sperling M,et al.Predictive estimate of blood dose from external counting data preceding radioiodine therapy for thyroid cancer.Nucl Med Biol,1993,20:157-162.
  • 6Hanscheid H,Lassmann M,Luster M,et al.Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer:procedures and results of a prospective international controlled study of ablation after thTSH or hormone withdrawal.J Nucl Med,2006,47:648-654.
  • 7Sgouros G.Blood and bone marrow dosimetry in radioiodine therapy of thyroid cancer.J Nucl Med,2005,46:899a-900a.
  • 8Hackshaw A,Harmer C,Mallick U,et al.^131I activity for remnant ablation in patients with differentiated thyroid cancer:a systematic review.J Clin Endocrinol Metab,2007,92:28-38.
  • 9Luster M,Clarke SE,Dietlein M,et al.Guidelines for radioiodine therapy of differentiated thyroid cancer.Eur J Nucl Med Mol Imaging,2008,35:1941-1959.
  • 10de Klerk JMH,Oyen WJG.The continuous debate in literature about the usage of ^131I dosing for the ablation of thyroid remnants and metastases.Miner Endocrinol,2009,24:57-59.

共引文献35

同被引文献37

引证文献5

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部